Table 1.
Prioritising systemic anticancer treatments. Taken from NICE guideline [NG161].
| Priority Level | Treatment |
|---|---|
| 1 | Curative treatment with a high (more than 50%) chance of success. Adjuvant or neoadjuvant treatment which adds at least 50% chance of cure to surgery or radiotherapy alone or treatment given at relapse. |
| 2 | Curative treatment with an intermediate (20% to 50%) chance of success. Adjuvant or neoadjuvant treatment which adds 20% to 50% chance of cure to surgery or radiotherapy alone or treatment given at relapse. |
| 3 | Curative treatment with a low (10% to 20%) chance of success. Adjuvant or neoadjuvant treatment which adds 10% to 20% chance of cure to surgery or radiotherapy alone or treatment given at relapse. Non-curative treatment with a high (more than 50%) chance of more than 1 year extension to life. |
| 4 | Curative treatment with a very low (0% to 10%) chance of success. Adjuvant or neoadjuvant treatment which adds less than 10% chance of cure to surgery or radiotherapy alone or treatment given at relapse. Non-curative treatment with an intermediate (15% to 50%) chance of more than 1 year extension to life. |
| 5 | Non-curative treatment with a high (more than 50%) chance of palliation or temporary tumour control and less than 1 year expected extension to life. |
| 6 | Non-curative treatment with an intermediate (15% to 50%) chance of palliation or temporary tumour control and less than 1 year expected extension to life. |